EnzymicalS AG 9. März 2022

Enzymicals AG Board of Supervisors Appoints New Management with Dr. Erik de Vries as CEO

The Supervisory Board of Enzymicals AG, consisting of Chairman Prof. Dr. Uwe Bornscheuer (Greifswald University), Dr. Martin Langer (BRAIN Biotech AG, ticker BNN.DE) and Prof. Dr. Dagmar Braun (Braun Beteiligungs GmbH), appointed Dr. Erik de Vries as the new CEO of Enzymicals AG. Alongside Dr. de Vries, Dr. Sebastian Schätzle is appointed as Chief Business Officer and Dr. David Liese as Chief Operating Officer. This team will ensure the long-term development of the company.

This management change was set in motion due to the health situation of the outgoing CEO Dr. Ulf Menyes’ at the end of last year. “I noticed that, due to my health, I could not lead Enzymicals with the commitment and energy anymore that I wished to. Fortunately, the Advisory Board and Dr. de Vries have agreed that I can help in the transition of my duties and responsibilities over to him and the team in the next few months, after which I will stay involved to assist Enzymicals as an advisor and coordinator of specific projects on a part-time basis,” said Dr. Menyes.

With the advances in biotechnology over the past several years, Enzymicals is excellently positioned in the market as a developer of chemo-enzymatic processes and technologies for pharma, food and beverage, fine chemicals and chemical industry – for instance technologies for enzymatic polymer degradations – from gram to ton scale.

Prof. Uwe Bornscheuer, Chairman of the Board of Enzymicals AG, stated: “On behalf of everybody at and around Enzymicals, I wish to express my deep gratitude to Dr. Ulf Menyes for his more than ten years of dedication to the company. He has well positioned Enzymicals in the market and we are looking forward to his valuable contributions as an advisor. With the newly formed management team around Dr. Erik de Vries, we expect further growth of the business of Enzymicals. We are looking forward to the years to come and fully support the team.“

“Enzymicals is positioned for a bright future. There is a lot of untapped potential in the market with the advent of the Bio-Economy and global sustainability goals. It is exciting to be leading Enzymicals AG and to work together with my management team and our group of expert employees,” added Dr. de Vries as the new CEO.

For more information

Produktion: - Enzyme - Feinchemikalien Forschungsschwerpunkte: - Entwicklung und Herstellung von Biokatalysatoren Dienst... [mehr]